Contact Information
David Horne, Ph.D.
  • Interim Director, Beckman Research Institute
  • Chair and Professor, Molecular Medicine
  • Deputy Director for Research
  • Director, Synthetic and Biopolymer Chemistry Core
  • Co-director, Drug Discovery and Structural Biology (DDSB) Core

Professional Experience


  • 2014 - present, Deputy Director for Research, City of Hope Comprehensive Cancer Center, Duarte, CA
  • 2012 - present, Interim Director, Beckman Research Institute of City of Hope, Duarte, CA
  • 2011 Associate Director, Beckman Research Institute of City of Hope, Duarte, CA
  • 2011 Co-Director, Drug Discovery and Structural Biology (DDSB) Core, Beckman Research Institute of City of Hope, Duarte, CA
  • 2009 - present, Co-leader, Developmental Cancer Therapeutics Program, City of Hope Comprehensive Cancer Center, Duarte, CA
  • 2008 - present, Chair, Department of Molecular Medicine, Beckman Research Institute of City of Hope, Duarte, CA
  • 2007 - 2008, Associate Chair, Department of Molecular Medicine, Beckman Research Institute of City of Hope, Duarte, CA
  • 2006 - present, Director, Synthetic and Biopolymer Chemistry Core Facility, Beckman Research Institute of City of Hope, Duarte, CA
  • 2006 Professor, Department of Molecular Medicine, Beckman Research Institute of City of Hope, Duarte, CA
  • 2004 Professor of Chemistry, Oregon State University, OR
  • 1998 Associate Professor of Chemistry, Oregon State University, OR
  • 1997 Associate Professor of Chemistry, Columbia University, New York City, NY
  • 1993 Adjunct Professor, Department of Biology, Columbia University, New York City, NY
  • 1992 Assistant Professor of Chemistry, Columbia University, New York City, NY
  • 1989 NIH Postdoctoral Fellow, California Institute of Technology, Pasadena, CA

Education

 
Education/Training
 
  • 1989 NIH Postdoctoral Fellow, California Institite of Technology, Pasadena, CA
  • 1988 Massachusetts Institute of Technology, Ph.D., Chemistry
  • 1984 University of California, Los Angeles, M.S., Chemistry
  • 1983 University of California, Los Angeles, B.S., Chemistry
 

Honors/Awards

 
Awards
 
  • 2004 Olaf Boedtker Faculty Inspiration Award, College of Science, Oregon State University
  • 2002 Harris Teaching Award, Department of Chemistry, Oregon State University
  • 2001 Lloyd Carter Teaching Award, College of Science, Oregon State University
  • 1996 Great Teacher Award, Honorable Mention, Columbia University
  • 1995 National Science Foundation Young Investigator Award
  • 1993 Becton-Dickson Fellow
  • 1992 Beckman Young Investigator Award
  • 1989 National Institutes of Health Postdoctoral Fellow

Honors

  • 2011 Member, Scientific Advisory Board, Arnold and Mabel Beckman Foundation
 

Memberships


  • 2013 Chair, NIH NCATS, TRND Study Section
  • 2013 Ad hoc Member, SBIR ((Biological Chemistry, Biophysics, and Drug Discovery) Study Section
  • 2009 Ad hoc Member, National Institutes of Health F32 Study Section
  • 2007 Ad hoc Member, National Institutes of Health K99-R00 Pathway to Independence Study Section
  • 2006 Ad hoc Member, National Institutes of Health SBCA Study Section
  • 2001 - 2006, Permanent Member, National Institutes of Health MCHA/SBCA Study Section
  • 2000 Ad hoc Member, National Institutes of Health MCHA Study Section
  • 1998 Ad hoc Member, National Institutes of Health MCHA Study Section
  • 1997 Ad hoc Member, National Institutes of Health MCHA Study Section

Publications


Representative Publications
 
  • Donaldson, J. M.; Zer, C.; Avery, K. N.; Bzymek, K. P.; Horne, D. A.; Williams, J. C. “Identification and grafting of a unique peptide-​binding site in the Fab framework of monoclonal antibodies” Proc. Natl. Acad. Sci., Early Edition (2013), (Oct 7 2013), 1-6.
  • DeLorbe, J. E.; Horne, D.; Jove, R.; Mennen, S. M.; Nam, S.; Zhang, F.-L.; Overman, L. E. “General Approach for Preparing Epidithiodioxopiperazines from Trioxopiperazine Precursors: Enantioselective Total Syntheses of (+)​- and (-​)​-​Gliocladine C, (+)​-​Leptosin D, (+)​-​T988C, (+)​-​Bionectin A, and (+)​-​Gliocladin A” J. Am. Chem. Soc. 2013, 135, 4117-4128.
  • Zhou, B.; Su, L.; Hu, S.; Hu, W.; Yip, M. L. R.; Wu, J.; Gaur, S.; Smith, D. L.; Yuan, Y.-C.; Synold, T. W.; Horne, D.; Yen, Y. “A small-​molecule blocking ribonucleotide reductase holoenzyme formation inhibits cancer cell growth and overcomes drug resistance” Cancer Res 2013, 73, 6484-6493.
  • Lu, L.; Zhang, W.; Nam, S.; Horne, D. A.; Jove, R.; Carter, R. G. “Amphidinolide B: total synthesis, structural investigation, and biological evaluation” J. Org. Chem. 2013, 78, 2213-2247.
  • Li, Y.-J.; Perkins, A. L.; Su, Y.; Ma, Y.; Colson, L.; Horne, D. A.; Chen, Y. “Gold nanoparticles as a platform for creating a multivalent poly-​SUMO chain inhibitor that also augments ionizing radiation” Proc. Natl. Acad. Sci. 2012, 109, 4092-4097.
  • Li, W.; Tian, E.; Chen, Z.-X.; Sun, G. Q.; Ye, P.; Yang, S.; Lu, D.; Xie, J.; Ho, T.-V; Tsark, W. M.; Wang, C.; Horne, D. A.; Riggs, A. D.; Yip, M. L. R.; Shi, Y. “Identification of Oct4-​activating compounds that enhance reprogramming efficiency” Proc. Natl. Acad. Sci. 2012, 109, 20853-20858.
  • Yuan, H.; Wang, Z.; Li, L.; Zhang, H.; Modi, H.; Horne, D.; Bhatia, R.; Chen, W. “Activation of stress response gene SIRT1 by BCR-​ABL promotes leukemogenesis” Blood 2012, 119, 1904-1914
  • Tian, Y.; Nam, S.; Liu, L.; Yakushijin, F.; Yakushijin, K.; Buettner, R.; Liang, W.; Yang, F.; Ma, Y.; Horne, D.; Jove, R. “Spirooxindole derivative SOID-​8 induces apoptosis associated with inhibition of JAK2​/STAT3 signaling in melanoma cells” PLoS One 2012, 7, e4930.
  • Singhal, S. S.; Figarola, J.; Singhal, J.; Leake, K.; Nagaprashantha, L.; Lincoln, C.; Gabriel Gugiu, B.; Horne, D.; Jove, R.; Awasthi, S.; Rahbar, S. "1,3-Bis(3,5-dichlorophenyl) urea compound ‘COH-SR4’ inhibits proliferation and activates apoptosis in melanoma" Biochem. Pharmacol. 201284 (11), 1419-1427.
  • Figarola, J. L.; Weng, Y.; Lincoln, C; Horne, D.; Rahbar, S. "Novel dichlorophenyl urea compounds inhibit proliferation of human leukemia HL-60 cells by inducing cell cycle arrest, differentiation and apoptosis" Invest. New Drugs 201230 (4), 1413-25.
  • Nam, S.; Xie, J.; Perkins, A.; Ma, Y.; Yang, F.; Wu, J.; Wang, Y.; Xu, R. Z.; Huang, W.; Horne, D. A.; Jove, R. "Novel synthetic derivatives of the natural product berbamine inhibit Jak2/Stat3 signaling and induce apoptosis of human melanoma cells" Molecular Oncology 20126 (5), 484-93.
  • Singhal, S. S.; Figarola, J.; Singhal, J.; Leake, K.; Nagaprashantha, L.; Lincoln, C.; Gabriel Gugiu, B.; Horne, D.; Jove, R.; Awasthi, S.; Rahbar, S. "1,3-Bis(3,5-dichlorophenyl) urea compound 'COH-SR4' inhibits proliferation and activates apoptosis in melanoma" Biochem. Pharmacol. 2012.
  • Xie, J.; Ma, Y.; Horne, D. A. "Asymmetric Synthesis of the Core Structure of Leucosceptroids A-D" J Org Chem 201176, 6169-76.
  • Xie, J.; Ma, Y.; Horne, D. A. "Total synthesis of the proposed structure of iriomoteolide-1a" Tetrahedron 201167, 7485-501.
  • Ma, Y.; Kowolik, C. M.; Swiderski, P. M.; Kortylewski, M.; Yu, H.; Horne, D. A.; Jove, R.; Caballero, O. L.; Simpson, A. J. G.; Lee, F. T.; Pillay, V.; Scott, A. M. "Humanized Lewis-Y Specific Antibody Based Delivery of STAT3 siRNA" ACS Chem. Biol 2011 DOI: 10.1021/cb200176v
  • Buettner, R.; Corzano, R.; Rashid, R.; Lin J. P.; Senthil, M.; Hedvat, M.; Schroeder, A.; Mao, A.; Herrmann, A.; Yim, J.; Li, H. Z.; Yuan, Y. C.; Yakushijin, K. I.; Yakushijin, F.; Vaidehi, N.; Moore, R.; Gugiu, G.; Lee, T. D.; Yip, R.; Chen, Y.; Jove, R.; Horne, D.; Williams, J. C. "Alkylation of Cysteine 468 in Stat3 Defines a Novel Site for Therapeutic Development" ACS Chem. Biol 20116, 432-43.
  • Xie J, Ma, Y.; Horne, D. A. "Total synthesis of the proposed structure of iriomoteolide-1a" Chem. Commun. (Cambridge, U. K.) 201046, 4770-72.
  • Miyake, F.; Hashimoto, M.; Tonsiengsom, S.; Yakushijin, K.; Horne, D. A. "Synthesis of 5-(3-indolyl)oxazole natural products" Structure revision of Almazole D. Tetrahedron 2010, 66, 4888-93.
  • Ma, Y.; Nam, S.; Jove, R.; Yakushijin, K.; Horne, D. A. "Synthesis and anticancer activities of ageladine A and structural analogs" Bioorg. Med. Chem. Lett. 201020, 83-86.
  • Lee, H.; Deng, J.; Kujawski, M.; Yang, C.; Liu, Y.; Herrmann, A.; Kortylewski, M.; Horne, D.; Somlo, G.; Forman, S.; Jove, R.; Yu, H. "STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors" Nat. Med. (N. Y., NY, U. S.) 201016, 1421-28.
  • Xie, J.; Ma, Y.; Horne, D. A. "Asymmetric Synthesis of the C(7)-C(23) Fragment of Iriomoteolide-1a" Org. Lett. 200911, 5082-84.
  • Xie, J.; Horne, D. "Stereoselective synthesis of iriomoteolide-1a hemiketal core" Tetrahedron Lett. 200950, 4485-87.
  • Ma, Y.; Yakushijin, K.; Miyake, F.; Horne, D. "A concise synthesis of indolic enamides: coscinamide A, coscinamide B, and igzamide" Tetrahedron Lett. 200950, 4343-45.
  • Tonsiengsom, F.; Miyake, F. Y.; Yakushijin, K.; Horne, D. A. "Reduction of 2,5-bis(3'-indolyl)pyrazines to 2,5-bis(3'-indolyl) piperazines: synthesis of bisindolylpiperazine marine alkaloids dragmacidin A, B, and C" Synthesis 2006, 49-54.
  • Miyake, F. Y.; Yakushijin, K.; Horne, D. A. "Biomimetic synthesis of grossularines-1" Angew. Chem., Int. Ed. 200544, 3280-82.
  • Shimizu, H.; Shimizu, K.; Kubodera, N.; Yakushijin, K.; Horne, D. A. "Efficient modification of steroid 20S-hydroxy functionality for industrial preparation of 1α,25-dihydroxy-22-oxavitamin D3, Maxacalcitol" Tetrahedron Lett. 200445, 1347-50.
  • Shimizu, H.; Shimizu, K.; Kubodera, N.; Yakushijin K; Horne, D. A. "Regioselective cleavage of trisubstituted epoxy-linkage using lithium trialkylborohydride reagents: A new route to the key intermediate of maxacalcitol" Heterocycles 200463, 1335-43.
  • Miyake, F. Y.; Yakushijin, K.; Horne, D. A. "A concise synthesis of spirotryprostatin A" Org. Lett. 20046, 4249-51.
  • Miyake, F. Y.; Yakushijin, K.; Horne, D. A. "Preparation and synthetic applications of 2-halotryptophan methyl esters: Synthesis of spirotryprostatin B" Angewandte Chemie-International Edition 200443, 5357-60.
  • Miyake, F. Y.; Yakushijin, K.; Horne, D. A. "Preparation and synthetic applications of 2-halotryptamines: Synthesis of elacomine and isoelacomine" Org. Lett. 20046, 711-13.
  • Castedo, M.; Perfettini, J. L.; Roumier, T.; Yakushijin, K; Horne, D.; Medema, R.; Kroemer, G. "The cell cycle checkpoint kinase Chk2 is a negative regulator of mitotic catastrophe" Oncogene 200423, 4353-61.
  • Castedo, M.; Perfettini, J. L.; Roumier, T.; Valent, A.; Raslova, H.; Yakushijin, K; Horne, D.; Feunteun, J.; Lenoir, G.; Medema, R.; Vainchenker, W.; Kroemer, G. "Mitotic catastrophe constitutes a special case of apoptosis whose suppression entails aneuploidy" Oncogene 200423, 4362-70.
  • Wiese, K. J.; Yakushijin, K.; Horne, D. A. "Synthesis of dibromophakellstatin and dibromoisophakellin" Tetrahedron Lett. 2002, 43 (29), 5135-36.
  • Miyake FY; Yakushijin, K.; Horne, D. A. "Synthesis of marine sponge bisindole alkaloids dihydrohamacanthins" Org. Lett. 20024, 941-3.
  • Barrios Sosa, A. C.; Yakushijin, K.; Horne, D. A. "Synthesis of axinohydantoins" J. Org. Chem. 200267, 4498-5000.
  • Miyake, F. Y.; Yakushijin, K.; Horne, D. A. "A facile synthesis of dragmacidin B and 2,5-bis(6 '-bromo-3 '-indolyl)piperazine" Org. Lett. 20002, 3185-87.
  • Miyake, F. Y.; Yakushijin, K.; Horne, D. A. "A concise synthesis of topsentin A and nortopsentins B and D" Org. Lett. 20002, 2121-23.
  • Barrios Sosa, A. C.; Yakushijin, K.; Horne, D. A. "Controlling cyclizations of 2-pyrrolecarboxamidoacetals. Facile solvation of [beta]-amido aldehydes and revised structure of synthetic homolongamide" Tetrahedron Lett. 200041, 4295-99.
  • Barrios Sosa, A. C.; Yakushijin, K.; Horne, D. A. "A practical synthesis of (Z)-debromohymenialdisine" J. Org. Chem. 200065, 610-1.
  • Barrios Sosa, A. C.; Yakushijin, K.; Horne, D. A. "Synthesis of slagenins A, B, and C" Org. Lett. 20002, 3443-44.
 

Patents

 
Representative Patents
 
  • Non-provisional patent application (USA) 14/083,938, “Photocleavable Linker” Filed: 11/19/2013.
  • PCT Application/US2013/066252 “ETP Derivatives” Filed: 10/22/2013.
  • Non-provisional patent application (USA) 13/953,013, “Novel Modulators and Development of Adipocyte and Cancer Cells” Filed: 7/29/2013.
  • Non-provisional application (USA) 13/776,374, “Isatin Derivatives, Pharmaceutical Compositions Thereof, and Methods of Use Thereof” Filed: 2/25/2013.
  • PCT Application/US2013/24490, “Synthesis of COH 29” Filed: 2/1/2013.
  • PCT Application/US2012/32938, “Meditopes and Meditope-Binding Antibodies and Uses Thereof” Filed: 4/10/2012.
  • Non-provisional patent application (USA) “Multi-Valent Poly-SUMO Chain Inhibitor and Methods of Use” 13/401,642, Filed: 2/21/2012.
  • PCT Application/US2012/23034, “Novel Modulators of Development of Adipocyte And Cancer Cells” Filed: 1/27/2012.
  • Non-provisional patent application (USA) “Humanized Lewis-Y Specific Antibody-Based Delivery of Dicer Substrate siRNA (D-siRNA) Against STAT3” 61/454,458, Filed: 3/18/2011.
  • Non-provisional patent application (USA) “Berbamine Derivatives” 12/783,535, Filed: 5/19/2010.
  • US Patent 8,163,783 “Ribonuclease Reductase Inhibitors and Methods of use” Issued: 4/25/2011.
  • US Patent 7,956,076 “Ribonuclease Reductase Inhibitors and Methods of use” Issued: 4/8/2009.
  • US Patent 7,615,638 “Synthesis of Grossularines-1 and Analogs Thereof and Method of Use” Issued: 4/30/2007.
  • U.S. Patent 6,841,658 “Methods for Making Bis-Heterocyclic Alkaloids” Issued: 1/11/2005.
  • U.S. Patent 6,211,361 “Method for Making Debromohymenialdisine and Analogs Thereof” Issued: 4/3/01.
  • U.S. Patent 6,197,954. “Intermediates for the Synthesis of Debromohymenialdisine and Processes Thereof” Issued: 3/6/01.
  • U.S. Patent 6,103,899. “Bicyclic Aminoimidazoles” Issued: 8/15/00.
  • PCT Int. Appl. (1998), WO 9809935. “Intermediates for the Synthesis of Vitamin D and Steroid Derivatives and Processes for Preparation Thereof” Issued: 3/12/98.
  • U.S. Patent 5,834,609. “Bicyclic Aminoimidazoles” Issued: 6/10/98.

Locations


  • City of Hope - Main Campus (Duarte)
    1500 East Duarte Road
    Duarte, CA 91010